Apitegromab: Risks & Legal Status
Important safety information, risks, and regulatory status
Important Safety Warnings
- Regulatory: Apitegromab has not been approved by any regulatory agency worldwide. The FDA BLA received a Complete Response Letter (CRL) related to manufacturing findings at the Catalent fill-finish facility. BLA resubmission is planned but approval timeline is uncertain.
- Access: Apitegromab is a monoclonal antibody (~150 kDa) that cannot be obtained from peptide suppliers or compounding pharmacies. It is only accessible through clinical trials or, upon approval, prescription. Any product sold online claiming to be apitegromab is fraudulent.
📌TL;DR
- •5 risk categories identified
- •2 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Apitegromab has not been approved by any regulatory agency worldwide. The FDA BLA received a Complete Response Letter (CRL) related to manufacturing findings at the Catalent fill-finish facility. BLA resubmission is planned but approval timeline is uncertain.
Apitegromab is a monoclonal antibody (~150 kDa) that cannot be obtained from peptide suppliers or compounding pharmacies. It is only accessible through clinical trials or, upon approval, prescription. Any product sold online claiming to be apitegromab is fraudulent.
The FDA CRL cited manufacturing observations at the Catalent fill-finish facility. While not related to drug efficacy or safety, manufacturing issues must be resolved before approval. This introduces regulatory uncertainty.
The absolute HFMSE improvement in SAPPHIRE was modest (1.8 points). While statistically significant, the clinical meaningfulness of this magnitude of improvement in individual patients varies. Long-term benefits beyond 12 months in a controlled setting are not established.
While up to 48 months of open-label TOPAZ extension data are available, very long-term effects of myostatin pathway inhibition are unknown. Theoretical concerns include cardiac effects, as myostatin is expressed in cardiac tissue.
⚠️Important Warnings
- •Apitegromab is an investigational drug that has not been approved by any regulatory agency. All information is based on clinical trial data only.
- •This is a monoclonal antibody (~150 kDa) that requires mammalian cell culture production and GMP manufacturing. It cannot be synthesized by peptide suppliers or compounding pharmacies.
- •IV administration requires clinical supervision and infusion infrastructure. It is not suitable for self-administration.
- •Any product sold online or through non-clinical channels claiming to be apitegromab should be considered fraudulent and potentially dangerous.
- •The FDA Complete Response Letter indicates unresolved manufacturing issues. Approval timeline is uncertain.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | - |
| European Union | Investigational | - |
| Global | Not approved | - |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 20+ community reports
View community protocolsCritical Safety Information#
Apitegromab (SRK-015) is an investigational monoclonal antibody that has not been approved for any indication by any regulatory agency worldwide. All clinical data comes from controlled clinical trials. The information below is provided for educational purposes only.
Regulatory Risk#
FDA Complete Response Letter#
The most significant near-term risk for apitegromab is regulatory uncertainty. The FDA issued a Complete Response Letter (CRL) for the BLA, citing manufacturing findings at the Catalent fill-finish facility. Key points:
- The CRL was not related to efficacy or safety -- the clinical data package was not cited as a concern
- Manufacturing observations related to the fill-finish process at Catalent
- Scholar Rock plans to resubmit the BLA after resolving the manufacturing issues
- Timeline for resubmission and potential approval remains uncertain
EMA Application#
The European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for review. The European regulatory path may proceed independently of the FDA manufacturing issues.
Clinical Limitations#
Modest Effect Size#
While SAPPHIRE met its primary endpoint with statistical significance, the absolute HFMSE improvement was modest:
| Metric | Value | Context |
|---|---|---|
| Mean HFMSE difference | +1.8 points | On a 66-point scale |
| Apitegromab arm change | +0.6 points | Modest absolute gain |
| Placebo arm change | -1.2 points | Natural decline prevented |
| Responder rate (>=3 points) | 30.4% vs 12.5% | ~70% did not reach this threshold |
The benefit appears to be primarily in preventing motor function decline rather than producing large absolute gains. For individual patients, the clinical meaningfulness of 1.8 points on the HFMSE varies.
Dose-Response Uncertainty#
SAPPHIRE tested both 10 mg/kg and 20 mg/kg doses but pooled them for the primary analysis. Individual dose-response differentiation was not clearly established, leaving uncertainty about optimal dosing.
Population Limitations#
- Only nonambulatory SMA Types 2 and 3 patients were studied in SAPPHIRE
- All patients required background SMN-targeted therapy (nusinersen or risdiplam)
- Type 1 SMA patients were not included
- Ambulatory patients were not the primary population
- Adult patients (over 21) were not studied
Long-Term Safety Considerations#
Known Safety Profile#
The short-term safety profile is favorable, with AE rates comparable to placebo in SAPPHIRE and up to 48 months of open-label data from the TOPAZ extension. No anti-drug antibodies have been detected across all trials.
Theoretical Concerns#
| Concern | Risk Level | Basis |
|---|---|---|
| Cardiac effects | Uncertain | Myostatin is expressed in cardiac tissue; long-term blockade effects unknown |
| Bone effects | Low | No bone safety signals observed in trials |
| Reproductive effects | Unknown | Not studied in pregnant women |
| Cancer risk | Low theoretical | No proliferative signals; myostatin may have tumor-suppressive roles |
| Immune effects | Very low | IgG4 subclass minimizes effector function; no immunogenicity observed |
Access Risks#
Not Available Outside Clinical Trials#
Apitegromab is currently accessible only through:
- Ongoing clinical trials (SAPPHIRE extension, EMBRAZE)
- Expanded access programs (if available from Scholar Rock)
It is not available through:
- Peptide suppliers or research chemical vendors
- Compounding pharmacies
- Online marketplaces or gray-market sources
Fraud Risk#
As a monoclonal antibody requiring mammalian cell culture and GMP manufacturing, apitegromab cannot be produced by peptide synthesis companies. Any product claiming to be apitegromab sold through non-pharmaceutical channels is fraudulent. Consumers should be aware that:
- Monoclonal antibodies (~150 kDa) cannot be made by peptide synthesis (limited to ~5-10 kDa)
- Production requires specialized bioreactors and purification systems
- No legitimate source exists outside of clinical trials or (upon approval) prescription pharmacies
- Claims of "research grade" apitegromab from online vendors should be treated as fraudulent
IV Administration Burden#
Unlike subcutaneous biologics, apitegromab requires:
- Travel to a clinical infusion center every 4 weeks
- Healthcare professional supervision during infusion
- Post-infusion monitoring period
- Significant time commitment per visit
For SMA patients already attending clinical centers for nusinersen infusions, this may be manageable. However, for the obesity indication, IV administration is a significant practical limitation compared to SC alternatives like trevogrumab or injectable GLP-1 agonists.
Risk-Benefit Summary#
| Patient Population | Benefit Level | Risk Level | Assessment |
|---|---|---|---|
| SMA Types 2/3 (nonambulatory, on SMN therapy) | Moderate (statistically significant motor improvement) | Low (placebo-like AE profile) | Favorable if approved |
| SMA Type 1 | Unknown | Unknown | Not studied |
| Obesity (with tirzepatide) | Moderate (lean mass preservation) | Low (well-tolerated in EMBRAZE) | Promising but early-stage |
| General muscle wasting | Unknown | Unknown | Not studied outside SMA/obesity |
Legal Status by Jurisdiction#
Apitegromab is not approved in any country. It holds investigational status globally:
- United States: BLA filed, CRL received for manufacturing. Fast Track, Orphan Drug, Rare Pediatric Disease designations
- European Union: MAA accepted for review. PRIME and Orphan Medicinal Product designations
- All other jurisdictions: Not approved, not submitted
Upon potential approval, apitegromab would be a prescription biologic administered in clinical settings, not a consumer product.
Related Reading#
Frequently Asked Questions About Apitegromab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.